1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Poster Session

Start Session

AML - 829

Comparison of Ivosidenib- and Venetoclax-Based Treatment Sequencing and Outcomes in Patients With mIDH1 AML: A Real-World Study

Vanessa Kennedy

Poster Presenter: Vanessa Kennedy

Thumbnail for All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

AML - 843

All-Oral Treatment in Patients Older Than 65 Years With Newly Diagnosed Acute Myelogenous Leukemia: Progression-Free Survival and Toxicity

Maher Salamoon

Poster Presenter: Maher Salamoon

$Thumbnail for Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis$

AML - 848

Efficacy and Differentiation Syndrome With Menin Inhibitors in Relapsed/Refractory KMT2A-Rearranged or NPM1-Mutated Acute Leukemia: An Exploratory Proportional Meta-Analysis

Farzeen Fatma Syed

Poster Presenter: Farzeen Fatma Syed

Thumbnail for Prevalence of Standard Modifiable Risk Factors and Associated Cardiovascular Events Among Patients Hospitalized With Acute Myeloid Leukemia: A Nationwide Inpatient Analysis (2016-2022)

AML - 849

Prevalence of Standard Modifiable Risk Factors and Associated Cardiovascular Events Among Patients Hospitalized With Acute Myeloid Leukemia: A Nationwide Inpatient Analysis (2016-2022)

Aishwarya Ramesh

Poster Presenter: Aishwarya Ramesh

AML - 851

FIRST-LINE TREATMENT OUTCOMES IN TP53-MUTATED ACUTE MYELOID LEUKEMIA: A SYSTEMATIC REVIEW AND META-ANALYSIS

Ali Mohamedi

Poster Presenter: Ali Mohamedi

Thumbnail for Comparative Toxicity of Menin Inhibitor-Based Combination therapy in newly diagnosed Acute Myeloid Leukemia: Venetoclax-containing Versus Non-Venetoclax regimens

AML - 858

Comparative Toxicity of Menin Inhibitor-Based Combination therapy in newly diagnosed Acute Myeloid Leukemia: Venetoclax-containing Versus Non-Venetoclax regimens

Vaishnavi Rao

Poster Presenter: Vaishnavi Rao

Thumbnail for Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

AML - 867

Postmarketing Safety Signals of Revumenib (Menin-KMT2A Inhibitor) vs Acute Myeloid Leukemia-Targeted Therapies: A Class-Restricted Disproportionality Analysis of the FDA Adverse Event Monitoring System (2016-2026)

Arashdeep Singh

Poster Presenter: Arashdeep Singh

Thumbnail for Characteristics and Clinical Outcomes of DDX41-Mutated Myeloid Neoplasms Treated with Lenalidomide: Single-Center Retrospective Study

AML - 872

Characteristics and Clinical Outcomes of DDX41-Mutated Myeloid Neoplasms Treated with Lenalidomide: Single-Center Retrospective Study

Jacob Herstein

Poster Presenter: Jacob Herstein

Thumbnail for Treatment Intensity Does Not Improve Survival in TP53-Mutated Acute Myeloid Leukemia: Real-World Outcomes From a Racially Diverse Academic Center

AML - 897

Treatment Intensity Does Not Improve Survival in TP53-Mutated Acute Myeloid Leukemia: Real-World Outcomes From a Racially Diverse Academic Center

Eiline Cai

Poster Presenter: Eiline Cai